NCT02341599View on ClinicalTrials.gov

Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects (MK-6183-001)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 11, 2014

Primary Completion Date

April 13, 2015

Study Completion Date

April 20, 2015

Conditions

Healthy VolunteersRenal Impairment

Interventions

DRUG

MK-6183

MK-6183 (CB-238,614) is supplied as lyophilized powder 500 mg vial and mixed into solution for 100 mL intravenous (IV) administration over 1 hour.

All Listed Sponsors

lead

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT02341599 - Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects (MK-6183-001) | Biotech Hunter | Biotech Hunter